AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation ConditioningTransplantation, HomologousMelphalanGranulocyte Colony-Stimulating FactorLeukapheresisCombined Modality TherapyHematologic NeoplasmsAntigens, CD34Blood Component RemovalStem Cell TransplantationCyclophosphamideMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsMyeloablative AgonistsBusulfanGraft vs Host DiseaseTreatment OutcomeLymphoma, Non-HodgkinGraft SurvivalBone Marrow TransplantationHematopoietic Stem CellsEtoposideThiotepaAntineoplastic Agents, AlkylatingRemission InductionRecurrenceCytophagocytosisCarmustineIfosfamideSalvage TherapyVincristineAmyloidosisStem CellsCytarabineHematopoiesisHodgkin DiseaseCord Blood Stem Cell TransplantationDisease-Free SurvivalTransplantation ChimeraRetrospective StudiesNeoplasmsTissue DonorsSurvival RateWhole-Body IrradiationInfectionLymphoma, T-CellSurvival AnalysisTime FactorsDoxorubicinHistocompatibilityPOEMS SyndromePlatelet CountHistocompatibility TestingPrednisoneCarboplatinImmunosuppressive AgentsLeukemia, Myeloid, AcuteTransplantation, IsogeneicDexamethasoneVidarabineBlood Cell CountRecombinant ProteinsFollow-Up StudiesLeukemiaBone Marrow PurgingAntineoplastic AgentsLymphomaCytomegalovirus InfectionsBlood CellsProspective StudiesGraft vs Leukemia EffectFatal OutcomeFeasibility StudiesMyelodysplastic SyndromesImmunophenotypingAnemia, AplasticBlood Transfusion, AutologousLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte DepletionLeukocytes, MononuclearT-LymphocytesHistiocytosis, Non-Langerhans-CellLivedo ReticularisOpportunistic InfectionsHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaHLA AntigensBone MarrowCyclosporineBlood DonorsPrognosisBreast NeoplasmsImmunosuppressionMesenchymal Stem Cell TransplantationCell Separation
Granulocyte-macropMultiple myelomaTransplantChemotherapyAllogeneic hematopoietic stem cUmbilicalMarrow transplantationMesenchymalHSCTHigh-doseMalignanciesSafety and efficacyMobilizeCD34LymphomasDiffuse large B-Progenitor cell2022LymphoidPBSCNonmyeloablativeSurvivalAbstractClinical trialsVeno-occlusiMSCsGraftMelphalanUndergoDoseTransplantsPost-transplantationDiseasesTumor cellsTherapiesDonorProliferation2021TherapyFeasibleImmuneLymphoproliferative disordersAdultMobilization and collectionFormulationPBSCTTherapeuticsTreatment
Granulocyte-macrop1
Multiple myeloma17
Transplant18
  • Risks of infection also vary with the type of transplant, the indication for transplantation, and other host factors. (medscape.com)
  • The transplant procedure requires the harvesting of hematopoietic stem cells from a donor. (medscape.com)
  • A hematopoietic stem cell transplant replaces faulty cells so the body can produce normal, healthy cells again. (mdanderson.org)
  • An autologous stem cell transplant uses the patient's own cells for treatment. (mdanderson.org)
  • An allogeneic stem cell transplant is similar, but we take cells from someone other than the patient. (mdanderson.org)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • With a peripheral blood cell transplant, the donor receives growth factor shots to stimulate the bone marrow to push the stem cells into the blood. (mdanderson.org)
  • The cells for a cord blood transplant come from an umbilical cord collected at birth by the MD Anderson Cord Blood Bank . (mdanderson.org)
  • For many patients who don't have a well-matched, healthy donor, a cord blood transplant is a viable option. (mdanderson.org)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoing unrelated donor transplant reported to the Center for International Blood and Marrow Transplant Research. (haematologica.org)
  • Successful outcomes following allogeneic hematopoietic cell transplant (HCT) may be offset by risks of transplant-related morbidity and mortality. (haematologica.org)
  • 1 Traditional factors used to gauge transplant risks include conditioning regimen intensity, 2 immunosuppression and HLA matching, 3 along with hematopoietic cell source, and graft cell yield. (haematologica.org)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • In the single autologous HCT arm, 129 of the 179 patients were subsequently given dinutuximab, an anti-GD2 monoclonal antibody, plus cytokine immunotherapy after single transplant consolidation therapy. (oncologynurseadvisor.com)
Chemotherapy18
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • Purpose: To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). (the-medical-dictionary.com)
  • Combination chemotherapy with cisplatin and etoposide (cisplatin-etoposide [PE]) has long been the mainstay of treatment for small cell lung cancer (SCLC). (the-medical-dictionary.com)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • It permits the administration of exceedingly high doses of chemotherapy, a practice that becomes viable due to the subsequent infusion of the patient's own stem cells. (medistateinternational.com)
  • This twofold approach not only harnesses the power of potent chemotherapy but also safeguards against bone marrow deficiency by replenishing the patient's stem cell count following the chemotherapy phase. (medistateinternational.com)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • All patients received multi-agent induction chemotherapy for 6 cycles, including an initial 2 cycles of high-dose cyclophosphamide plus topotecan followed by blood stem cell collection. (oncologynurseadvisor.com)
  • After completion of induction chemotherapy, patients were randomly assigned to receive a single autologous HCT with CEM (carboplatin, etoposide, melphalan) chemotherapy or a double/tandem autologous HCT with thiotepa plus cyclophosphamide prior to the first transplantation followed by a modified CEM regimen prior to the second. (oncologynurseadvisor.com)
Allogeneic hematopoietic stem c1
Umbilical6
  • The stem cell source may be bone marrow, peripheral blood, or umbilical cord blood. (medscape.com)
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • Whereas TNS contains biosignals obtained from cultured fibroblasts (skin cells from human infant foreskins), most other products are based on the culture of stem cells obtained from bone marrow, adipose tissue (fat), umbilical cord, and even (shocking to us! (barefacedtruth.com)
  • HSCT is the transplantation of stem cells, usually derived from the bone marrow, peripheral blood, or umbilical cord blood, to produce additional normal healthy blood cells, including T-cells. (smart-immune.com)
  • Furthermore, we have developed an automated process with selection techniques to generate CAR-T cells from umbilical cord blood T cells as well as conventional peripheral blood lymphocyte harvests from healthy donors. (ukri.org)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
Marrow transplantation10
Mesenchymal6
  • In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
  • Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) have been shown to counter rheumatoid arthritis, autoimmune hepatitis, and systemic sclerosis [ 8 ]. (biomedcentral.com)
  • PLX-R18 cells, derived from mesenchymal-like cells collected from donated placentas, are designed to release a combination of therapeutic proteins to jumpstart the regeneration of a poorly functioning hematopoietic system. (drugdiscoverynews.com)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. (biomedcentral.com)
  • There are many studies involving autologous therapies and some allogenic therapies, based on the recovery of mobilized bone marrow cells, including mesenchymal stem cells (MSCs) and adipose derived stem cells that also include the stromal or adherent cell type that has an MSC phenotype. (biomedcentral.com)
HSCT18
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • Hematopoietic stem cell transplantation (HSCT) is a broad term that covers the transplantation of blood progenitor/stem cells from any source. (drugdiscoverynews.com)
  • Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
  • GVHD, which is common among allogenic HSCT and rare in autologous HSCT, can be acute or chronic. (drugdiscoverynews.com)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • and phase mended strategies for preventing OIs in HSCT patients. (cdc.gov)
  • 3, the late phase (1100 days post-HSCT). (cdc.gov)
  • PHASES OF IMMUNE RECOVERY specialists, HSCT unit and clinic staff, and public health pro- fessionals. (cdc.gov)
  • HSCT may be autologous (the patient's stem cells are used) or allogeneic (the stem cells come from a donor). (smart-immune.com)
  • Smart Immune's ProTcell platform is designed to reconstitute a T-cell compartment in around three months , compared with 12-18 months through the standard HSCT approach, significantly reducing the time to full immune recovery and possibly opening access to allogeneic medicine to more patients. (smart-immune.com)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
High-dose2
Malignancies3
  • A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. (fredhutch.org)
  • TheIntroduction later step is unique to splenic function since splenectomy results in similar accumulations of naïve B cells, reduction of memory B cells and Treatment of malignancies with allogeneic peripheral blood stem well-known susceptibilities to select infections [12]. (fliphtml5.com)
  • Other leukaemia including T cell malignancies and acute myeloid leukaemia should be amenable to similar approaches. (ukri.org)
Safety and efficacy2
  • In the SIMPLIFY-1 multicenter, randomized, double-blind, phase III study, safety and efficacy of momelotinib was compared with ruxolitinib in 432 patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. (medscape.com)
  • This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis . (ucsd.edu)
Mobilize1
  • G-CSF was found to mobilize both CD34+ stem cells (p=0.02)and even more dramatically mobilize Hox11+ splenic stem cells (p=0.000013) into the peripheral blood. (fliphtml5.com)
CD344
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • Enrichment of PBSCT by purification of CD34+stem cells fails to produce superior clinical benefits. (fliphtml5.com)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
Lymphomas4
  • Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. (astct.org)
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
Diffuse large B-5
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
Progenitor cell9
  • Smart Immune announced in October 2022 that SMART102, a human T-cell progenitor cell injection derived from cord blood using the ProTcell platform, has entered clinical testing with the first adult patient treated. (smart-immune.com)
  • Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. (southcarolinablues.com)
  • Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic cardiac ischemia and for refractory angina. (southcarolinablues.com)
  • For individuals who have acute cardiac ischemia who receive progenitor cell therapy, the evidence includes 2 randomized controlled trials (RCTs) with 200 patients, numerous small RCTs, and meta-analyses of these RCTs. (southcarolinablues.com)
  • Overall, this evidence has suggested that progenitor cell treatment may be a promising intervention, but robust data on clinical outcomes are lacking. (southcarolinablues.com)
  • For individuals who have chronic cardiac ischemia who receive progenitor cell therapy, the evidence includes a nonrandomized comparative trial and systematic reviews of smaller RCTs. (southcarolinablues.com)
  • Results of the nonrandomized trial are encouraging, because this is the first controlled trial that has reported a significant mortality benefit for progenitor cell treatment. (southcarolinablues.com)
  • For individuals who have refractory angina who receive progenitor cell therapy, the evidence includes phase 2 trials and a phase 3 pivotal trial. (southcarolinablues.com)
  • Additional larger trials are needed to determine whether progenitor cell therapy improves health outcomes in patients with refractory angina. (southcarolinablues.com)
20221
Lymphoid2
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • indicated that ATMs colocalized with T cells in lymphoid clusters within adipose tissue and may act as APCs, which express high levels of MHCII and also costimulatory molecules and process and present antigens to induce CD4+ T-cell proliferation and activation in adipose tissue of obese mice (29, 68, 105). (exposed-skin-care.net)
PBSC1
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
Nonmyeloablative3
Survival8
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • The survival of patients diagnosed in this phase is 1-1.5 years. (medscape.com)
  • 6 Comorbidity determined by the hematopoietic cell transplantation-comorbidity index (HCT-CI), 7 predicts for worse survival, generally through higher TRM. (haematologica.org)
  • Our hypothesis about a splenic stem cell contributionor maintained survival compared to bone marrow transplants, to PBSCT also derives from the observation that G-CSF mobilizationsalthough graft versus host disease (GVHD) still occurs [1]. (fliphtml5.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. (immunetolerance.org)
  • Results showed that 3-year event-free survival was 48.4% ± 3.8% with single autologous HCT compared with 61.4% ± 3.7% with tandem autologous HCT ( P =.0081). (oncologynurseadvisor.com)
  • The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
Abstract1
  • Invited discussant for this abstract Dominique Valteau-Couanet, MD, PhD, head of the pediatric and adolescent oncology department at Institut Gustave Roussy in France, questioned which patients actually benefit from tandem autologous HCT: patients with localized disease and MYCN amplification? (oncologynurseadvisor.com)
Clinical trials8
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • In recent years, clinical trials with stem cells have taken the emerging field in many new directions. (biomedcentral.com)
  • The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson (2009) [ 1 ]. (biomedcentral.com)
  • There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine. (biomedcentral.com)
  • We have chosen to concentrate on the emerging therapeutics that broadly involves a wide range of cell types in clinical trials registered on the National Institutes of Health's clinical trials web site. (biomedcentral.com)
  • The public clinical trials database http://clinicaltrials.gov shows 123 clinical trials using MSCs for a very wide range of therapeutic applications (Figure 1 ), the majority of which are in Phase I (safety studies), Phase II (proof of concept for efficacy in human patients), or a mixture of PhaseI/II studies (Figure 2 ). (biomedcentral.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Veno-occlusi1
MSCs4
  • One trial is testing whether MSCs with or without peripheral blood stem cells could treat poor graft function and delayed platelet engraftment. (drugdiscoverynews.com)
  • In another trial, this group is evaluating whether peripheral blood stem cells combined with MSCs can treat poor graft function. (drugdiscoverynews.com)
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • The use of patient's own bone marrow aspirates, hematopoietic stem cells and MSCs, for heart muscle tissue repair can be puzzling because these cells do not normally contribute to the cardiac lineage types that are desired. (biomedcentral.com)
Graft7
  • However, T-cell depletion is associated with higher rates of graft rejection and increased vulnerability to viral and fungal infections while the T-cell population is diminished. (medscape.com)
  • All patients achieved initial mixed hematopoietic chimerism with two patients rejecting their graft and recovering host hematopoiesis. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • Journal Article] Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph+ALL with minimal residual disease. (nii.ac.jp)
Melphalan1
Undergo2
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • Eligible subjects will undergo hematopoietic stem cell (HSC) mobilization and collection (leukapheresis). (ucsd.edu)
Dose4
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Because pilot studies of tandem autologous HCT demonstrated tolerable toxicity and potential efficacy and because prior trials have demonstrated that dose intensification improves outcomes, researchers decided to explore tandem transplantation in patients with high-risk neuroblastoma. (oncologynurseadvisor.com)
Transplants7
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • To understand the different types of stem cell transplants and how they work, we spoke with Borje S. Andersson, M.D., Ph.D. Here's what he had to say. (mdanderson.org)
  • What are the types of stem cell transplants? (mdanderson.org)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • Citation: Mera T, Heimfeld S, Faustman DL (2014) The Spleen Contributes Stem Cells to Peripheral Blood Stem Cell Transplants. (fliphtml5.com)
  • Interestingly, thiscell transplants (PBSCTs) from donors given granulocyte-colony- immature peripheral phenotype was similar to bone marrow transplantsstimulating-factor (G-CSF) has decreased relapse rates and improved before G-CSF. (fliphtml5.com)
  • For induce splenomegaly in most donors and in rare, severe cases splenicautologous stem cell transplants, the use of autologous PBSCT from rupture [13,14]. (fliphtml5.com)
Post-transplantation1
  • The assessment follow-up period will include an initial 2 years of active end-point evaluations, where the subjects will be evaluated at 3-, 6-, 9-, 12-, 18- and 24-months post-transplantation. (ucsd.edu)
Diseases9
  • In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)
  • Furthermore, stem cell transplantation proves invaluable in addressing various familial diseases, each marked by distinct trajectories that primarily manifest during childhood. (medistateinternational.com)
  • Hereditary diseases encompass a vast spectrum, with differing suitability for stem cell transplantation. (medistateinternational.com)
  • However, for certain hereditary diseases characterized by severe, life-threatening, or progressive courses, stem cell transplantation may present a lifeline. (medistateinternational.com)
  • More research teams are accelerating the use of other types of adult stem cells, in particular neural stem cells for diseases where beneficial outcome could result from either in-lineage cell replacement or extracellular factors. (biomedcentral.com)
  • The failure of the immune system to function as it should, can result from immune deficiencies present at birth, acquired diseases such as blood cancers, medications that suppress or damage the immune system, unnecessary or over-the-top immune responses such as allergies, or immune responses to one's self, called autoimmunity. (smart-immune.com)
  • Smart Immune is working to improve the prognosis of immune-compromised patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. (smart-immune.com)
  • Endothelial progenitor cells (EPCs) contribute to neovascularization and play an important role in the development of these diseases. (hindawi.com)
  • In this study, in attempt to provide fresh information about the impact of CS on proliferation of EPCs to elucidate the pathophysiological mechanisms of the diseases related to CS in cellular level, we assessed the proliferation of EPCs after interfering the cells with a series of concentrations of CSE for various times of exposure in vitro . (hindawi.com)
Tumor cells5
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • Our emerging clinical data demonstrates that these gene-modified T cells are very active in killing tumor cells initially, but they lose their ability to function within a few weeks. (ca.gov)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
Therapies11
  • Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
  • hEPCs have been used for cell-based therapies due to their capacity to contribute in the re-endothelialization of injured blood vessels and neovascularization in ischemic tissues. (intechopen.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • T-cell therapies can be manufactured from different materials (mature T-cells, stem cells, possibly induced pluripotent stem cells) and from different sources (the patient or a donor). (smart-immune.com)
  • Smart Immune is the first company to develop thymus-empowered allogeneic T-cell therapies and advance them into clinical testing through its T-cell progenitor platform, ProTcell. (smart-immune.com)
  • Researchers are working to train T-cells to recognize specific types of cancer by developing CAR T-cell therapies. (smart-immune.com)
  • CAR T-cell therapies can be compared to a personalized radar that target a specific type of cancer. (smart-immune.com)
  • Several CAR T-cell therapies are already on the market and available for patients in the USA and the European Union. (smart-immune.com)
  • ProTcell is Smart Immune's thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, aimed at enabling next-generation allogeneic T-cell therapies for all. (smart-immune.com)
  • Universal T cells aim to circumvent HLA barriers and provide an 'off-the-shelf' alternative to autologous cell therapies. (ukri.org)
  • Beyond T cell/CAR therapies, the terminal-CRISPR vector configuration is being applied to a correction of single gene disorders of the haematopoietic system and skin disorders, and will be of broad interest to the field. (ukri.org)
Donor14
  • In autologous transplantation, the donor and recipient is the same individual. (medscape.com)
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • This allows us to collect more cells in a short period, decrease patient/donor downtime and freeze the cells for future use. (mdanderson.org)
  • If the donor cells aren't a close enough match, the patient's body may recognize the donor cells as foreign and reject them. (mdanderson.org)
  • Or, the cells from the donor may recognize the new body as foreign and attack. (mdanderson.org)
  • of these, 53 percent are autologous (taken from the patient) and 47 percent are allogenic (taken from a donor other than the patient). (drugdiscoverynews.com)
  • In such cases, the transplantation procedure is prioritized during the early stages, provided a suitable donor is identified. (medistateinternational.com)
  • The decision to proceed with stem cell transplantation for these conditions hinges on a comprehensive evaluation of the disease's course, severity, donor-related attributes, and procedural risks. (medistateinternational.com)
  • The success of stem cell transplantation pivots on the identification of a donor possessing either a fully-matched or partially-matched tissue group with the patient. (medistateinternational.com)
  • Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-TK and the truncated ΔLNGFR for selection of transduced cells. (frontiersin.org)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • We recently showed that its possible not only to arm cells against leukaemia but also disarm them to stop side effects if they are taken from a healthy donor and transplanted to a patient without any matching. (ukri.org)
Proliferation5
  • Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
  • Imatinib inhibits proliferation and induces apoptosis in cells positive for BCR/ABL . (medscape.com)
  • Splenomegaly might reflect dramatic G-CSF-inducedG-CSF stimulation also in multiple studies shows faster recovery of Hox11+ stem cell proliferation. (fliphtml5.com)
  • showed that adipose tissue from obese mice induced proliferation of splenic CD8+ T cells, indicating a CD8+ T cell-activating environment in obese adipose tissue (31). (exposed-skin-care.net)
  • Scaffolds play an important role in tissue engineering as a substrate that can mimic the native extracellular matrix and the properties of scaffolds have been shown to affect the cell behavior such as the cell attachment, proliferation and differentiation. (wjgnet.com)
20211
Therapy23
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
  • The ORR was 64% in patients with prior T-cell redirecting therapy. (medscape.com)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
  • Stem cell transplantation is a valuable supplementary therapy for CD. (biomedcentral.com)
  • Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. (biomedcentral.com)
  • A strategy in the treatment of cancer by harnessing the immune system, called adoptive cell therapy, is to use an individual's own immune cells (T cells) and genetically modify them to target them to kill the cancer. (ca.gov)
  • This chapter provides an overview of the key role of hEPC in promoting angiogenesis and their potential use for cell therapy. (intechopen.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • In all three phases, supportive therapy with transfusions of red blood cells or platelets may be used to relieve symptoms and improve quality of life. (medscape.com)
  • The chronic phase varies in duration, depending on the maintenance therapy used: it usually lasts 2-3 years with hydroxyurea (Hydrea) or busulfan therapy, but it may last for longer than 9.5 years in patients who respond well to interferon-alfa therapy. (medscape.com)
  • This phase is characterized by poor control of the blood counts with myelosuppressive medication and the appearance of peripheral blast cells (≥15%), promyelocytes (≥30%), basophils (≥20%), and platelet counts less than 100,000 cells/μL unrelated to therapy. (medscape.com)
  • The decision to proceed with transplantation hinges on a thorough assessment of patients' chances for successful results, along with a comprehensive understanding of therapy-related risks. (medistateinternational.com)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • What is T-cell therapy? (smart-immune.com)
  • This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (COMFORT-I) 1 or best available therapy (COMFORT-II) 2 in JAK inhibitor-naïve patients with myelofibrosis. (org.in)
  • This was a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea. (org.in)
  • FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (org.in)
  • FDA granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (org.in)
  • New treatments for leukaemia using gene therapy to re-program white bloods cells against cancer cells are showing a great deal of promise. (ukri.org)
  • The therapy will aim to induce molecular remission & thereby secure eligibility for allogeneic stem cell transplantation. (ukri.org)
  • A number of these children may be suitable for autologous CAR therapy, but manufacturing is often problematic, especially in small infants. (ukri.org)
  • The Food and Drug Administration approved a treatment that uses gene therapy to treat severe hemophilia A, a rare and sometimes fatal blood disorder. (cdc.gov)
Feasible1
Immune8
  • The transplanted cells kill any remaining cancer cells and restore the patient's immune system. (mdanderson.org)
  • The purpose of the current study is to give gene-modified T cells in combination with gene-modified stem cells to reprogram the immune system to recognize and kill cancer cells that have the NY-ESO-1 protein with sustained killing activity. (ca.gov)
  • Gene modification of cells involves the transfer of foreign genetic material (DNA) into a cell, in this case the immune system cells and stem cells. (ca.gov)
  • This process will endow the recipient immune cells and descendants of the stem cells with the ability to eliminate cancer cells that express the cancer specific protein, NY-ESO-1. (ca.gov)
  • The specific receptor against cancer cells that will be transferred to the immune cells and stem cells is called NY-ESO-1 T cell receptor (or TCR). (ca.gov)
  • In this study, the gene-modified immune cells will be given in combination with the gene-modified stem cells. (ca.gov)
  • A significant proportion of clinical studies that are underway involve bone marrow and cord blood stem cells for blood and immune disorders [ 3 ] and cancers. (biomedcentral.com)
  • Rearming their immune system with a new compartment of fully functional T-cells would allow them to defend themselves against any threats. (smart-immune.com)
Lymphoproliferative disorders1
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
Adult2
  • Human endothelial progenitor cells (hEPCs) are adult stem cells, located in the bone marrow and peripheral blood. (intechopen.com)
  • This is a non-therapeutic study for patients at St. Jude Children's Research Hospital and Methodist Adult Comprehensive Sickle Cell Center . (stjude.org)
Mobilization and collection1
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
Formulation2
  • These products therefore contain cells or cell parts in their formulation. (barefacedtruth.com)
  • Doxorubicin liposomal is a pegylated formulation that protects the liposomes and, thereby, increases blood circulation time. (medscape.com)
PBSCT1
Therapeutics2
  • Pluristem Therapeutics, based in Haifa, Israel, is currently recruiting patients in the United States and Israel for its Phase 1 trial of PLX-R18 cells in this unmet need. (drugdiscoverynews.com)
  • Placenta-derived stem cells are being considered for similar uses and are in Phase III clinical trial for critical limb ischemia by Israel's Pluristem Therapeutics. (biomedcentral.com)
Treatment10
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • The major goal of treatment during this phase is to control symptoms and complications resulting from anemia , thrombocytopenia , leukocytosis, and splenomegaly. (medscape.com)
  • The standard treatment of choice is now imatinib mesylate (Gleevec), which is a specific small-molecule inhibitor of BCR/ABL in all phases of CML. (medscape.com)
  • The procedure of bone marrow / peripheral stem cell transplantation serves as a pivotal treatment avenue for patients contending with a spectrum of medical challenges. (medistateinternational.com)
  • Often, conventional medical treatment options are limited, leaving stem cell transplantation as a potential game-changer. (medistateinternational.com)
  • The treatment usually involves a remission induction phase aimed at establishing a complete remission and a postinduction phase aimed at eradicating "occult" residual disease. (ashpublications.org)
  • 1 Treatment with progenitor cells (i.e., stem cells) offers potential benefits beyond those of standard medical care, including the potential for repair and/or regeneration of damaged myocardium. (southcarolinablues.com)
  • In the meantime, improvements in the way we modify cells have led to the development of new versions of the treatment that we think are going to be more widely used. (ukri.org)
  • Around 10-15% go on to develop relapsed refractory cases and may fail to respond to aggressive treatment, including allogeneic stem cell transplantation. (ukri.org)